Last reviewed · How we verify

Hexapen — Competitive Intelligence Brief

Hexapen (Mecillinam) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mecillinam. Area: Metabolic.

marketed mecillinam Penicillin-binding protein 2 Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Hexapen (Mecillinam) — Roche. Hexapen works by inhibiting bacterial cell wall synthesis, preventing the bacteria from producing a strong cell wall.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hexapen TARGET Mecillinam Roche marketed mecillinam Penicillin-binding protein 2
Pivamdinocillin pivmecillinam Sykehuset i Vestfold HF marketed pivmecillinam

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (mecillinam class)

  1. Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hexapen — Competitive Intelligence Brief. https://druglandscape.com/ci/mecillinam. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: